Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery


24 Nov 2018


Poster display - Cocktail


Radiation Oncology

Tumour Site

Breast Cancer


Kannan Periasamy


Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426


K. Periasamy1, S. Cholayil1, G. Karunanithi1, K. Dharanipragada2, V. Neelakandan1

Author affiliations

  • 1 Radiation Oncology, JIPMER, 605006 - Pondicherry/IN
  • 2 General Surgery, JIPMER, 605006 - Pondicherry/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 873


Tumour bed boost irradiation is an integral part of breast conservative treatment. The various techniques for delivering tumour bed boost include electrons, photons, and interstitial brachytherapy. Volumetric modulated arc therapy (VMAT) is a novel radiation treatment technique. The purpose of the study is to compare high dose rate (HDR) interstitial brachytherapy (BT) with VMAT for tumour bed boost following breast conservative treatment in terms of local control, acute skin toxicity and cosmesis.


50 patients with early stage breast cancer [Stage I-II] who underwent breast conservation surgery were randomized to either HDR interstitial brachytherapy group (n = 25) or VMAT group (n = 25) for tumour bed boost. All patients in both groups received whole breast irradiation of 46Gy in 23 fractions. The patients in the brachytherapy group received perioperative interstitial HDR BT of 15Gy in 6 fractions over a period of 3 days as boost and whole breast irradiation was delivered after a gap of 2-3 weeks. For patients in the VMAT group, irradiation to the whole breast was delivered first, followed by sequential tumour bed boost of 16Gy in 8 fractions. Chemotherapy and hormonal therapy were given as indicated. Local control, acute skin toxicity and breast cosmesis were assessed.


At a median follow up of 8.5 months, there were no local recurrences observed in both the arms. The acute skin toxicity was similar in both the groups. No grade 4 toxicity was observed; one patient in each group developed grade 3 toxicity. At 3 months, the rate of excellent/good cosmesis was similar for the 2 groups by observer evaluation. According to patient self-evaluation, breast cosmesis was rated as excellent/good in 84% of patients treated with VMAT and 92% of patients treated with HDR BT.


Both modalities of tumour bed boost irradiation were similar in local control, acute skin toxicity and cosmetic outcome. VMAT has the advantage of better patient acceptance as it is non-invasive and less painful when compared to interstitial brachytherapy. Studies with higher sample size and longer follow up are needed to quantify the absolute benefit of each modality with respect to local control and breast cosmesis.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Institute Ethics Committee, JIPMER.


JIPMER Intramural research fund.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.